India : BIOSIMILAR in Europe launched by Intas Pharmaceuticals.
Intas Pharmaceuticals has introduced their first biosimilar, filgrastim, in Europe, through their wholly-owned subsidiary Accord Healthcare. The product has lately been launched under the brand Accofil and has by now secured two tenders, in Netherlands and the UK respectively. Additionally, Intas is in addition the only company from India to have 2 of its products, filgrastim and peg-filgrastim filed for registration in the US, through its association partner.
Accofil is a biosimilar product of Neupogen (filgrastim) and will present patients cost effective therapy that is comparable in quality, safety and efficacy. Accofil is indicated for the treatment of decrease in the duration of neutropenia and the incidence of febrile neutropenia, mobilisation of peripheral blood progenitor cells, severe congenital, cyclic, or idiopathic neutropenia and persistent neutropenia in patients with advanced HIV infection.
Binish Chudgar, Vice-Chairman, Intas Pharmaceuticals said, The launch of our filgrastim in Europe is another demonstration of our commitment to global healthcare at affordable prices. Accofil (filgrastim), which was developed at our own laboratories and manufactured at our own cGMP approved site in Ahmedabad, showcases our expertise in biopharmaceutical development and its manufacture. This is only the first of many biological products that we will launch in EU and other regulated markets over the next few years.
2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 24, 2015|
|Previous Article:||Ireland,Switzerland : DATALEX becomes technology partner at SWISS INTERNATIONAL AIR LINES.|
|Next Article:||India : INDIAN Army and SBI sign MOU.|